LIFE - aTyr Pharma, Inc.
aTyr Pharma, Inc.
3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States
858 731 8389
https://www.atyrpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 65
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | Pres, CEO & Director | 795.48k | N/A | 1972 |
| Ms. Jill M. Broadfoot | Chief Financial Officer | 556.62k | N/A | 1962 |
| Ms. Nancy E. Denyes Krueger | Gen. Counsel & Corp. Sec. | 532.13k | N/A | 1968 |
| Xiang-Lei Yang Ph.D. | Founder | N/A | N/A | N/A |
| Ms. Ashlee Dunston | Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
| Mr. Peter Villiger | VP of Corp. Devel. | N/A | N/A | N/A |
| Ms. Danielle Campbell | VP of Human Resource | N/A | N/A | N/A |
| Dr. Leslie Nangle Ph.D. | VP of Research | N/A | N/A | N/A |
| Dr. Ying J. Buechler Ph.D. | Exec. Director of Biologics Devel. & Manufacturing | N/A | N/A | N/A |
| Dr. David J. King | Scientific Consultant | N/A | N/A | 1959 |
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Corporate Governance
aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
